Dr. McDermott on Immunotherapy as a Standard of Care in RCC

David F. McDermott, MD
Published: Thursday, Dec 28, 2017



David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

According to McDermott, immunotherapy will be the standard of care for patients with RCC in 2018; however, it will not benefit everyone.

Patients with good-risk clinical features did very well with sunitinib (Sutent) in the CheckMate-214 trial, so there may be some patients who could benefit from single-agent VEGF inhibitors, explains McDermott.

SELECTED
LANGUAGE


David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

According to McDermott, immunotherapy will be the standard of care for patients with RCC in 2018; however, it will not benefit everyone.

Patients with good-risk clinical features did very well with sunitinib (Sutent) in the CheckMate-214 trial, so there may be some patients who could benefit from single-agent VEGF inhibitors, explains McDermott.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x